Table 4– Treatment characteristics of 1,027 multidrug-resistant tuberculosis (MDR-TB) cases, stratified by non-extensively drug-resistant (XDR)-TB and XDR-TB status, Latvia, 2000–2004#
Non-XDR-TBXDR-TBp-value
Cases n97948
Treatment characteristics
Duration of therapy days
Cure599 (538–671)641 (547–857)0.10+
Completion618 (386–665)
Death183 (88–448)113 (86–171)0.36+
Default201 (124–296)260 (103–680)0.51+
Failure348 (227–502)378 (316–600)0.13+
Total cohort552 (376–640)525 (323–680)0.79+
Number of resistant drugs used for ≥3 months<1 (0–1)2 (1–2)<0.001+
Culture conversion
Started therapy culture-negative208 (21.2)3 (6.3)Ref
Never converted among those culture-positive at initiation153 (19.8)26 (57.8)<0.001
Time to initial conversion among those who converted days62 (34–109)52 (28–118)0.84+
Conversion by 62 days among those who converted310 (50.2)11 (57.9)0.50
Interruption of treatment
For ≥5 weeks435 (44.4)23 (47.9)0.63
For <5 weeks544 (55.6)25 (52.1)Ref
Missing ≥40 doses
Yes368 (37.6)16 (33.3)0.55
No611 (62.4)32 (66.7)Ref
Adverse events during treatment
Any759 (77.5)39 (81.2)0.55
None220 (22.5)9 (18.8)Ref
Adverse events reported per person3 (1–6)4 (1–6)0.53+
  • Data are presented as n (%) or median (interquartile range), unless otherwise stated. Ref: reference. #: year 2000 for civilians only; : data are presented as mean (95% CI); +: Wilcoxon rank-sum test.